Is ICANN Policymaking Around Its Bottom-Up Multistakeholder Process? 12/04/2013 by Monika Ermert for Intellectual Property Watch Leave a Comment This week, registry, registrar and user constituencies at the Internet Corporation for Assigned Names and Numbers (ICANN) complained about what they saw as deviations from the bottom-up multistakeholder process by late additions made to policies or by processes never being laid out to the community for review.
New SMS Tool To Report Non-Tariff Trade Barriers At African Borders 12/04/2013 by Intellectual Property Watch Leave a Comment Small traders and businesses facing barriers to moving goods across African borders now can send a mobile phone text message alert that could help resolve the problems more quickly.
Debate In Beijing: ICANN As Online Content Regulator? 12/04/2013 by Monika Ermert for Intellectual Property Watch Leave a Comment The publication by governments of additional safeguards for new top-level domains at this week‘s 46th meeting of the Internet Corporation for Assigned Names and Numbers (ICANN) sparked warnings that the private net management body should avoid becoming a content regulator.
Reports: Obama’s Proposed 2014 Budget Favours Patent Office, R&D, Generic Drugs 11/04/2013 by William New, Intellectual Property Watch 1 Comment US President Barack Obama yesterday released his proposed budget for fiscal year 2014, and according to reports it would give the US Patent and Trademark Office (USPTO) control over its revenues, and would be mixed for the biopharmaceutical industry while taking several steps to boost generic medicines.
Community Right To Access Unpublished Works Trumps Moral Rights Of Heir, Argentine Court Says 11/04/2013 by Maximiliano Marzetti for Intellectual Property Watch 1 Comment In a recent decision, Ediciones de la Flor SA c. Fontanarrosa Franco s. Acción Mere Declarativa (File No. 1420/08), the Court of First Instance in Civil and Commercial Matters No. 12 of Rosario, the second largest city in Argentina, ruled that the rights of the community to access unpublished works of a deceased author are superior to the moral rights of one of his heirs to oppose such publication.
Questions Follow Sharp Rise In Investor-State Disputes, Far-Reaching Cases 10/04/2013 by William New, Intellectual Property Watch Leave a Comment At an unprecedented rate, private companies are using “investor-state” provisions in trade agreements negotiated by governments to challenge foreign government regulations, often made on behalf of the public, a United Nations report has found. And the majority of target governments are developing or transition economies, most of the time being challenged by companies in developed countries.
Lack Of Progress In Closing Digital Divide Gap, Says World Economic Forum 10/04/2013 by Intellectual Property Watch 1 Comment A significant gap remains in advanced and developing economies’ access to information technologies, according to the 2013 “Global Information Technology Report” released today by the World Economic Forum.
South Korea Military Fights High Price Of Patented R&D 10/04/2013 by Intellectual Property Watch Leave a Comment Korea Intellectual Property Office (KIPO) Commissioner Young-min Kim has joined military leaders and patent attorneys in signing a “Working agreement for the building of a military intellectual property (IP) ecosystem.” A key aim is to avoid high-cost private-sector patent monopolies on military R&D.
New Draft Traditional Knowledge Bill Published In South Africa 10/04/2013 by Intellectual Property Watch 2 Comments An alternative South African bill on the protection of traditional knowledge has been published in the official Government Gazette, and it would create a new system of intellectual property right specific to TK, according to South Africa experts.
Study: Misuse Of Patent System Affecting Health System In Australia 10/04/2013 by Intellectual Property Watch Leave a Comment Research from the University of Melbourne has found that patents may be keeping pharmaceuticals expensive in Australia, but said that most of the patents are being taken out by companies that are not the originators of the drugs.